Drug intelligence / Profile preview

AdCLD-CoV19-1 LP.8.1

Development stage: Preclinical
Lead developer: Cellid
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

AdCLD-CoV19-1 LP.8.1 is an adenovirus-based viral vector vaccine candidate developed by the South Korean biotechnology company Cellid. It is designed to prevent COVID-19 by targeting the spike protein of the SARS-CoV-2 LP.8.1 variant, which aligns with the WHO recommendations for the 2025 strain. The vaccine utilizes a replication-deficient adenovirus vector to deliver the antigen-encoding DNA into host cells, stimulating both humoral and cellular immune responses. As of early 2025, the program is in the preclinical stage of development.

Other names: AdCLD-CoV19-1 (LP.8.1)

Targets

CD46 (CD46 Molecule)Severe acute respiratory syndrome coronavirus 2 spike glycoprotein (LP.8.1 variant)

Beyond the preview

Go deeper on AdCLD-CoV19-1 LP.8.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdCLD-CoV19-1 LP.8.1.

Explore the full profile